Basic Information
PECFENT NASAL SPRAY SOLUTION 100 MCG/SPRAY
SPRAY, METERED
Regulatory Information
SIN16026P
October 12, 2020
Prescription Only
Therapeutic
NASAL
August 10, 2023
June 3, 2025
XN02AB03
Company Information
A. MENARINI SINGAPORE PTE. LTD.
A. MENARINI SINGAPORE PTE. LTD.
Active Ingredients
Strength: 100 μg/spray
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Patients without maintenance opioid therapy as there is an increased risk of respiratory depression. Severe respiratory depression or severe obstructive lung conditions. Treatment of acute pain other than breakthrough pain. Patients being treated with medicinal products containing sodium oxybate.
Indication Information
**4.1 Therapeutic indications** PecFent is indicated for the management of breakthrough pain (BTP) in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.